Molecular Docking and Dynamics Simulation of Novel Small-Molecule Inhibitors Targeting Mutant KRAS G12D in Pancreatic Cancer
DOI:
https://doi.org/10.5281/zenodo.22662649Keywords:
KRAS G12D, molecular docking, molecular dynamics simulation, pancreatic ductal adenocarcinoma, MRTX1133Abstract
Background: KRAS G12D is the most prevalent oncogenic KRAS variant in pancreatic ductal adenocarcinoma, yet unlike KRAS G12C
it lacks a reactive cysteine handle for covalent drug design, forcing reliance on purely non-covalent, salt-bridge-anchored inhibitor
strategies. Objective: This review synthesizes the computational drug-discovery literature on molecular docking and molecular
dynamics (MD) simulation approaches used to identify and validate small-molecule KRAS G12D inhibitors, framed against the
clinically validated G12C paradigm (sotorasib, adagrasib). Methods: A narrative synthesis was performed using peer-reviewed
sources identified through PubMed/MEDLINE and Crossref searches, with each candidate reference individually verified against its
publisher record before inclusion; sources were organized thematically into the structural basis of the G12C-versus-G12D
drug-design problem, docking-based virtual screening methodology, and MD-based binding stability and free-energy estimation.
Findings: Non-covalent G12D inhibitors, exemplified by MRTX1133, achieve potency through a salt bridge to the mutant Asp12
residue and hydrogen bonding to His95 within an induced-fit switch-II pocket; docking programs such as AutoDock Vina and Glide
are used for large-library hit triage, while GROMACS-based MD simulation with MM/PBSA or MM/GBSA free-energy estimation is
required to distinguish genuinely stable binding poses from docking artifacts, a distinction directly demonstrated in
microsecond-scale simulations comparing MRTX1133 with repurposed comparator drugs. Conclusions: Molecular docking and MD
simulation play complementary, non-redundant roles in KRAS G12D drug discovery, and continued progress will depend on
pharmacophore filtering built explicitly around the Asp12 salt bridge, routine MD-based selectivity and resistance-anticipation
modeling, and translation of computational leads into the durable clinical benefit already achieved for KRAS G12C-directed
therapy.
References
Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chatterjee D, Hurd MW, Nikzad N, Wolff RA, Rashid A, Katz MHG, Snyder RA, Wang H, Maitra A, Overman MJ, Pant S (2024) Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precision Oncology, 8:27, DOI:10.1038/s41698-024-00505-0.
Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1):12-49, DOI:10.3322/caac.21820.
Khan N, Raza U, Zaidi SAA, Nuer M, Abudurousuli K, Paerhati Y, Aikebaier A, Zhou W (2025) Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. Cancer Biology & Medicine, 22(7):762-788, DOI:10.20892/j.issn.2095-3941.2025.0122.
Vetter IR, Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science, 294(5545):1299-1304, DOI:10.1126/science.1062023.
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 503(7477):548-551, DOI:10.1038/nature12796.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT (2020) KRASG12C inhibition with sotorasib in advanced solid tumors. New England Journal of Medicine, 383(13):1207-1217, DOI:10.1056/NEJMoa1917239.
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine, 384(25):2371-2381, DOI:10.1056/NEJMoa2103695.
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI (2022) Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. New England Journal of Medicine, 387(2):120-131, DOI:10.1056/NEJMoa2204619.
Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ (2023) Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. New England Journal of Medicine, 388(1):44-54, DOI:10.1056/NEJMoa2212419.
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS (2023) Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. New England Journal of Medicine, 388(1):33-43, DOI:10.1056/NEJMoa2208470.
Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y, Du Y, Chen CC, Guo RT, Zhang Y (2022) KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery, 8:5, DOI:10.1038/s41421-021-00368-w.
Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, Hallin J, Laguer J, Lawson JD, Medwid J, Newhouse B, Nguyen P, O'Leary JM, Olson P, Pajk S, Rahbaek L, Rodriguez M, Smith CR, Tang TP, Thomas NC, Vanderpool D, Vigers GP, Christensen JG, Marx MA (2022) Identification of MRTX1133, a noncovalent, potent, and selective KRAS G12D inhibitor. Journal of Medicinal Chemistry, 65(4):3123-3133, DOI:10.1021/acs.jmedchem.1c01688.
Wang Y, Zhang H, Li J, Niu MM, Zhou Y, Qu Y (2022) Discovery of potent and noncovalent KRASG12D inhibitors: structure-based virtual screening and biological evaluation. Frontiers in Pharmacology, 13:1094887, DOI:10.3389/fphar.2022.1094887.
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2):455-461, DOI:10.1002/jcc.21334.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7):1739-1749, DOI:10.1021/jm0306430.
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7:42717, DOI:10.1038/srep42717.
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5):449-461, DOI:10.1517/17460441.2015.1032936.
Abraham MJ, Murtola T, Schulz R, Pall S, Smith JC, Hess B, Lindahl E (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2:19-25, DOI:10.1016/j.softx.2015.06.001.
Hou T, Wang J, Li Y, Wang W (2010) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling, 51(1):69-82, DOI:10.1021/ci100275a.
Ancy I, Penislusshiyan S, Ameen F, Chitra L (2024) Microsecond molecular dynamics simulation to gain insight into the binding of MRTX1133 and trametinib with KRAS G12D mutant protein for drug repurposing. Journal of Molecular Recognition, 37(6):e3103, DOI:10.1002/jmr.3103.
Kano Y (2026) Precision targeting of KRAS-mutant cancers: beyond G12C toward G12D and pan-RAS therapeutic strategies. International Journal of Molecular Sciences, 27(13):5796, DOI:10.3390/ijms27135796.
